Clinical trials
Tolerance clinical trials
Below are recruiting tolerance clinical trials, each written for real people, not researchers. We’re tracking 940 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06828848RecruitingPhase 2
Study of Vaborem in children with Gram negative infections
This trial tests how Vaborem is absorbed and tolerated in children with serious bacterial infections, including complicated urinary tract infections. It aims to find the right dose for children.
OstravaAges birth–17 years - NCT06826196RecruitingPhase 1/Phase 2
Testing a new shot for patchy hair loss (alopecia areata)
This study tests a new medicine called ALD-102, given as a small shot in the scalp, to see if it helps hair grow back in people with alopecia areata. It is an early-stage trial looking at safety, how the body handles the drug, and whether it works.
Thousand Oaks, CaliforniaAges 18–55 - NCT06825702RecruitingPhase 2
Testing KIO-104 eye injection for macular edema
This trial tests an eye injection called KIO-104 to treat macular edema (swelling in the center of the retina) caused by conditions like uveitis, diabetes, or vein blockage. The goal is to see if it is safe and improves vision.
Sydney, New South WalesAges 18–85 - NCT06832982RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug that may help people with advanced solid tumors, including liver, stomach, and brain cancers. It is for patients whose cancer has not responded to standard treatments or who cannot have them. The study aims to find the right dose and check safety and effectiveness.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06830343RecruitingPhase 1
Safety study of SYH9017 for overweight and obesity
This study tests a new medication called SYH9017 for people who are overweight or have obesity. It aims to see how safe the drug is, how well it is tolerated, and how the body processes it. Participants will receive either the drug or a placebo and be monitored closely.
Beijing, Beijing MunicipalityAges 18–60 - NCT06829563RecruitingPhase 1
Testing safety of new diabetes drug RZ-629
This early-phase study tests a new medicine called RZ-629. It looks at how safe it is, how the body processes it, and how it works in both healthy people and people with type 2 diabetes. If you have diabetes, you can join if your blood sugar is well controlled on your current pills.
AdelaideAges 18–65 - NCT06676384RecruitingPhase 4
Testing additional drugs for IgA nephropathy in South Asian patients
This trial is testing if adding another approved drug to standard treatment can slow kidney function decline in people with IgA nephropathy. It aims to find better options for South Asian adults with this condition.
Nadiād, GujaratAges 18–65 - NCT06821503RecruitingPhase 1/Phase 2
Study of LM-108 with chemo for advanced pancreatic cancer
This trial tests a new drug called LM-108 combined with chemotherapy for people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if it's safe and may help shrink tumors or stop them from growing.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06817668Recruiting
Testing a new radiation approach for prostate cancer
This study is testing a new way of giving radiation for prostate cancer, called ePUHRT, combined with a standard brachytherapy boost (a small radioactive implant placed inside the prostate). It aims to see if this approach is well-tolerated and safe for people with higher-risk prostate cancer.
Indianapolis, IndianaAges 18 years+ - NCT06820658Recruiting
Comparing muscle response in active and inactive older adults
This study looks at how muscles respond to exercise in people aged 60 to 85. You will be asked to do some exercises so researchers can measure how your nerves and muscles work together.
Rochester, MinnesotaAges 60–85 - NCT06804824RecruitingPhase 1
Testing a new drug for advanced solid tumors with certain gene changes
This study tests an experimental drug called VVD-159642 in people with advanced solid tumors that have specific genetic changes (RAS or EGFR alterations, or HER2 overexpression). The goal is to see if the drug is safe and tolerable.
Grand Rapids, MichiganAges 18 years+ - NCT06813651RecruitingPhase 2
TBO-309 for stroke with tandem blockage
This trial tests whether adding TBO-309 to standard treatment helps people having a stroke caused by two blockages (one in the neck, one in the brain). It may limit brain damage and improve recovery.
Newcastle, New South WalesAges 18 years+ - NCT06810544RecruitingPhase 1/Phase 2
Study of TNG456 for tumors with MTAP loss
This trial tests a new drug called TNG456, alone or with another drug (abemaciclib), for people whose tumors have lost the MTAP gene. It aims to see if the combination can shrink tumors or slow their growth.
Scottsdale, ArizonaAges 18 years+ - NCT06809179RecruitingPhase 2
Nasal spray for social anxiety
This study tests if a new nasal spray called fasedienol helps quickly reduce anxiety in adults with social anxiety disorder. The spray is used as needed in a repeat-dose design, meaning you might use it more than once.
Sherman Oaks, CaliforniaAges 18–65 - NCT06809114RecruitingPhase 1
Study of AT03-65 for advanced CLDN6-positive solid tumors
This early-phase trial tests an investigational drug (AT03-65) for people with advanced solid tumors that have a certain protein called CLDN6. The goal is to see if the drug is safe and if it might help shrink tumors.
Denver, ColoradoAges 18 years+ - NCT06808984RecruitingPhase 2
Testing a new drug for agitation in Alzheimer's disease
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
Homewood, AlabamaAges 55–90 - NCT06814717RecruitingPhase 2
Study of cP12 for adults with small burns
This trial tests a new drug called cP12 given through a vein to see if it is safe and how the body handles it. It is for adults who have a thermal burn covering 10% or less of their body within the first 2 to 24 hours after the burn happened.
Washington D.C., District of ColumbiaAges 18–65 - NCT06800729RecruitingPhase 1
Testing safety of TIX100 in healthy volunteers
This phase 1 study tests an experimental drug called TIX100 in healthy volunteers to check its safety and how the body processes it. The results will help determine if the drug can be studied in future trials for conditions like obesity or metabolic disorders.
Chula Vista, CaliforniaAges 18–70 - NCT06794541RecruitingPhase 2
Testing eravacycline for kids with serious belly infections
This trial tests an antibiotic called eravacycline for children (ages 8–17) with serious belly infections. The medicine is given through an IV in the hospital to see if it is safe and tolerable.
Los Angeles, CaliforniaAges 8–17 - NCT06801002RecruitingPhase 1
Safety trial of JBZ-001 for advanced cancers
This trial tests a new drug, JBZ-001, to see how safe it is for people with advanced solid tumors or certain types of lymphoma that have not improved with standard treatments. It's a first-in-human study, so participants will help doctors learn about the drug's side effects and the right dose.
Columbus, OhioAges 18 years+ - NCT06793371RecruitingPhase 2
Study of CK-4021586 for heart failure with preserved ejection fraction
This trial tests an investigational drug called CK-4021586 for people with heart failure with preserved ejection fraction (HFpEF). It aims to see if the drug is safe and well-tolerated. You may qualify if you are 40 to 85, have heart failure symptoms, and have a heart that pumps well but shows signs of strain.
Fairhope, AlabamaAges 40–85 - NCT06800612Recruiting
Cancer drug therapy study for gynecologic or breast cancers
This study looks at how well different cancer drugs work for women with breast or gynecologic cancers. Researchers will review medical records to see how patients responded to treatment over time. If you have been treated for breast or gynecologic cancer since 2010, you may be eligible.
BolognaAges 18 years+ - NCT06801470RecruitingPhase 1
Testing the safety of CD-001 in advanced solid tumors
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
TianjinAges 18 years+ - NCT06786676RecruitingPhase 1
Safety study of AS-S603 in healthy volunteers
This trial tests a new drug called AS-S603 in healthy volunteers to see if it is safe and how the body processes it. It is an early-phase study for people of Korean or Caucasian background.
SeoulAges 19–85
Hear when a new Tolerance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tolerance?
- Yes. Clin2 currently lists 940 recruiting tolerance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tolerance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tolerance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.